IOVA Q2 2023 Earnings — Iovance Biotherapeutics, Inc. Revenue & Financial Results | Market Cap Arena

IOVAIovance Biotherapeutics, Inc.

$2B

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$238,000

Gross Profit

-$2M-761.3% margin

Operating Income

-$110M-46254.6% margin

Net Income

-$107M-44759.7% margin

EPS (Diluted)

$-0.47

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$94M

Free Cash Flow

-$103M

Stock-Based Comp.

$17M

Balance Sheet

Total Assets

$757M

Total Liabilities

$179M

Stockholders' Equity

$579M

Cash & Equivalents

$230M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$238,000	$0	—
Gross Profit	-$2M	$0	—
Operating Income	-$110M	-$100M	-10.4%
Net Income	-$107M	-$99M	-7.2%

Revenue Segments

Product

$200,000100%

Geographic Segments

Non-US

$200,000100%